- Home
- NPCE
NPCE
Neuropace Inc.
as 05-20-2024 9:35am EST
$.
-
$.
-.%
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 382.0M | IPO Year: | 2021 |
| Target Price: | $17.00 | AVG Volume (30 days): | 122.2K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.80 - $18.15 | Next Earning Date: | 05-08-2024 |
| Revenue: | $69,073,000 | Revenue Growth: | 42.07% |
| Revenue Growth (this year): | 17.25% | Revenue Growth (next year): | 17.54% |
Share on Social Networks:
Stock Insider Trading Activity of Neuropace Inc. (NPCE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | NPCE | 10% Owner | Apr 24 '24 | Sell | $14.06 | 1,781 | $25,040.86 | 3,435,541 | SEC Form 4 |
| ORBIMED ADVISORS LLC | NPCE | 10% Owner | Apr 16 '24 | Sell | $14.01 | 14,069 | $197,106.69 | 3,504,898 | SEC Form 4 |
| ORBIMED ADVISORS LLC | NPCE | 10% Owner | Apr 16 '24 | Sell | $14.15 | 300 | $4,245.00 | 3,504,598 | SEC Form 4 |
| ORBIMED ADVISORS LLC | NPCE | 10% Owner | Apr 16 '24 | Sell | $14.06 | 2,623 | $36,879.38 | 3,501,975 | SEC Form 4 |
| ORBIMED ADVISORS LLC | NPCE | 10% Owner | Apr 11 '24 | Sell | $14.49 | 461,899 | $6,692,916.51 | 3,542,068 | SEC Form 4 |
| ORBIMED ADVISORS LLC | NPCE | 10% Owner | Apr 11 '24 | Sell | $14.42 | 23,101 | $333,116.42 | 3,518,967 | SEC Form 4 |
| Morrell Martha | NPCE | Chief Medical Officer | Feb 2 '24 | Sell | $15.07 | 14,143 | $213,122.28 | 81,208 | SEC Form 4 |
| Morrell Martha | NPCE | Chief Medical Officer | Feb 2 '24 | Sell | $15.17 | 3,446 | $52,278.23 | 77,762 | SEC Form 4 |
| Morrell Martha | NPCE | Chief Medical Officer | Dec 26 '23 | Sell | $10.00 | 102 | $1,020.00 | 123,327 | SEC Form 4 |
| Morrell Martha | NPCE | Chief Medical Officer | Dec 26 '23 | Sell | $10.12 | 13,300 | $134,647.87 | 110,027 | SEC Form 4 |
| Morrell Martha | NPCE | Chief Medical Officer | Dec 6 '23 | Sell | $8.16 | 11,005 | $89,773.29 | 126,159 | SEC Form 4 |
| KCK LTD. | NPCE | 10% Owner | Nov 29 '23 | Sell | $8.72 | 5,644 | $49,215.68 | 5,604,296 | SEC Form 4 |
| KCK LTD. | NPCE | 10% Owner | Nov 29 '23 | Sell | $8.84 | 7,282 | $64,372.88 | 5,597,014 | SEC Form 4 |
| KCK LTD. | NPCE | 10% Owner | Nov 29 '23 | Sell | $8.73 | 3,241 | $28,293.93 | 5,593,773 | SEC Form 4 |
| KCK LTD. | NPCE | 10% Owner | Nov 27 '23 | Sell | $8.96 | 6,490 | $58,150.40 | 5,614,621 | SEC Form 4 |
| KCK LTD. | NPCE | 10% Owner | Nov 27 '23 | Sell | $8.75 | 4,681 | $40,958.75 | 5,609,940 | SEC Form 4 |
Latest Neuropace Inc. News
NPCE Breaking Stock News: Dive into NPCE Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
NeuroPace to Participate in Two Healthcare Conferences in May
Insider Monkey
7 days ago
NeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call Transcript
MT Newswires
7 days ago
Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating
GuruFocus.com
10 days ago
NeuroPace Inc (NPCE) Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Ongoing Challenges
GuruFocus.com
11 days ago
NeuroPace Inc (NPCE) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Improved ...
GlobeNewswire
12 days ago
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
a month ago
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
TipRanks
2 months ago